Pharmaceutical

FDA approves Amneal’s DHE migraine/cluster headache autoinjector

The US Food and Drug Administration has granted approval to Amneal Pharmaceuticals’ Brekiya (dihydroergotamine (DHE) mesylate) autoinjector.

May 18, 2025 - 06:00
FDA approves Amneal’s DHE migraine/cluster headache autoinjector
The US Food and Drug Administration has granted approval to Amneal Pharmaceuticals’ Brekiya (dihydroergotamine (DHE) mesylate) autoinjector.
Read the original article

Tags:

Previous Article

Influence of high-energy milling on the biological activity of microbial particles.

Next Article

Revamping US pharma manufacturing: Trump’s executive order faces industry doubts

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves BeiGene’s TEVIMBRA for oesophageal cancer

FDA approves BeiGene’s TEVIMBRA for oesophageal cancer

Mar 16, 2024

FDA clears Pfizer’s meningococcal disease vaccine

FDA clears Pfizer’s meningococcal disease vaccine

Oct 23, 2023

For pharma companies, the possibilities of green chemistry are huge

For pharma companies, the possibilities of green chemis...

Nov 1, 2024